Form 4: Aerovate Therapeutics Officer Benjamin T. Dake Executes Stock Option and Sells Shares Under 10b5-1 Plan

Benjamin T. Dake, an officer at Aerovate Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 1, 2024, Benjamin T. Dake, President, Chief Operating Officer and Secretary of Aerovate Therapeutics, Inc. [AVTE], executed a transaction involving the company's common stock.
• Dake exercised a stock option to acquire 3,325 shares at a price of $10.61 per share.
• Simultaneously, Dake sold 3,325 shares of common stock at a weighted average price of $31.9749, with individual sales ranging from $31.95 to $32.415.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 16, 2023.
• Following these transactions, Dake directly owns 1,291 shares of common stock and 25,675 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports insider trading activity under a pre-existing plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It is common for executives to utilize 10b5-1 trading plans to diversify their holdings and avoid accusations of trading on inside information. The filing itself doesn't provide specific insight into the company's performance or future prospects, but it does indicate that an insider is selling shares.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their insiders.
• The use of a 10b5-1 trading plan is a common and accepted method for corporate insiders to manage their stock holdings.
• The reported transactions are similar to those seen by officers at comparible companies such as Biohaven, United Therapeutics, and Acceleron Pharma.

Stakeholder Impact

• The sale of shares by an officer could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates